Giving crushed prasugrel to patients with ST-segment elevation myocardial infarction (STEMI) en route to the hospital for planned PCI* does not improve reperfusion rates compared with giving the tablets whole in the COMPARE CRUSH trial.
Patients with ST-elevation and COVID-19 have different characteristics than those without COVID-19, and may have a higher risk of in-hospital mortality and stroke, according to initial results of the NACMI* registry study presented at TCT Connect 2020.
The use of paclitaxel drug-coated devices did not appear to affect mortality risk in patients with symptomatic peripheral artery disease (PAD) who underwent endovascular lower extremity revascularization, according to subgroup analysis of the VOYAGER PAD* trial.
A daily, 4-gram dose of icosapent ethyl (IPE) led to a significant reduction in ischaemic events in a subgroup of patients from the REDUCE-IT* cohort who had prior PCI**, according to the prespecified analysis of the REDUCE-IT PCI trial presented at TCT 2020.
In select patients with advanced heart failure (HF), use of MitraClip as bridge therapy to heart transplantation appeared to be a promising strategy to reduce worsening and progression of underlying disease while awaiting transplant, suggests the MitraBridge study, even implying that post-procedural improvements may drive the removal of patients from the transplant list.
In patients with critical limb ischaemia (CLI) due to chronic total occlusions in the infrapopliteal region, drug-coated balloon (DCB) angioplasty was associated with a lower rate of late lumen loss compared with the standard balloon angioplasty – percutaneous transluminal angioplasty (PTA), according to the results of the IN.PACT below-the-knee (BTK) feasibility study presented at TCT 2020.
Treatment with dual antiplatelet therapy (DAPT) after PCI* can safely be shortened to 1 or 3 months without raising ischaemic risk in select patients with high bleeding risk, according to the XIENCE 90/28 trials presented at TCT 2020.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.